Quick Answer
Edwards Lifesciences Corp reported Cash and Equivalents of $2.94 billion for fiscal year 2025.
Edwards Lifesciences Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.94B | -3.5% |
| 2024 | $3.05B | +168.9% |
| 2023 | $1.13B | +47.2% |
| 2022 | $769.00M | -10.9% |
| 2021 | $862.80M | -27.1% |
| 2020 | $1.18B | +0.3% |
| 2019 | $1.18B | +65.1% |
| 2018 | $714.10M | -12.7% |
| 2017 | $818.30M | -12.0% |
| 2016 | $930.10M | +29.5% |
| 2015 | $718.40M | +9.9% |
| 2014 | $653.80M | +55.5% |
| 2013 | $420.40M | +35.2% |
| 2012 | $310.90M | +81.6% |
| 2011 | $171.20M | -29.8% |
| 2011 | $244.00M | +39.0% |
| 2011 | $175.60M | -46.0% |
| 2011 | $325.20M | -17.9% |
| 2010 | $396.10M | +18.6% |
| 2009 | $334.10M | +52.8% |
| 2008 | $218.70M | +54.2% |
| 2007 | $141.80M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.69B | -27.0% | -17.9% |
| June 30, 2025 | $3.27B | +99.0% | +4.2% |
| March 31, 2025 | $3.14B | +156.5% | +3.1% |
| December 31, 2024 | $3.05B | +168.9% | -17.2% |
| September 30, 2024 | $3.68B | +160.7% | +123.6% |
| June 30, 2024 | $1.64B | +57.7% | +34.3% |
| March 31, 2024 | $1.22B | +40.4% | +8.2% |
| December 31, 2023 | $1.13B | +47.2% | -19.7% |
- Edwards Lifesciences Corp showed a decrease of -3.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, Edwards Lifesciences Corp’s cash and equivalents has grown by 1971.9% (from $141.80 million to $2.94 billion).
- The most recent figure is from Edwards Lifesciences Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: